Ongoing research continues to explore Berberines potential therapeutic benefits in treating metabolic, cardiovascular, and inflammatory disorders
A 2025 systematic review, Vasireddi et al., HSS J 2025, screened hundreds of articles and found the BPC-157 orthopaedic base to be almost exclusively animal or low-level studies, with only isolated small human reports and no rigorous randomised trials
for people without a deficiency, evidence for additional benefit is limited, and B12 injections are not FDA approved for weight loss
Asymptomatic cholelithiasis was noted in 36.8%, 21.1%, 10.5%, and 31.6% of patients with dulaglutide, semaglutide, liraglutide, and control groups, respectively
We want to promote fat loss but preserve muscle
Wegovy (Semaglutide) : A separate study found an average weight loss of 15% over 68 weeks